HeartSciences (HSCS) Liabilities and Shareholders Equity (2022 - 2026)
HeartSciences filings provide 5 years of Liabilities and Shareholders Equity readings, the most recent being $7.6 million for Q1 2026.
- On a quarterly basis, Liabilities and Shareholders Equity rose 32.45% to $7.6 million in Q1 2026 year-over-year; TTM through Jan 2026 was $24.2 million, a 22.34% decrease, with the full-year FY2025 number at $4.2 million, down 55.56% from a year prior.
- Liabilities and Shareholders Equity hit $7.6 million in Q1 2026 for HeartSciences, up from $6.0 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $10.8 million in Q1 2024 to a low of $2.1 million in Q2 2022.
- Median Liabilities and Shareholders Equity over the past 5 years was $5.6 million (2022), compared with a mean of $5.6 million.
- Biggest five-year swings in Liabilities and Shareholders Equity: surged 228.38% in 2024 and later plummeted 55.56% in 2025.
- HeartSciences' Liabilities and Shareholders Equity stood at $4.8 million in 2022, then plummeted by 50.36% to $2.4 million in 2023, then surged by 228.38% to $7.8 million in 2024, then decreased by 22.9% to $6.0 million in 2025, then grew by 25.99% to $7.6 million in 2026.
- The last three reported values for Liabilities and Shareholders Equity were $7.6 million (Q1 2026), $6.0 million (Q4 2025), and $6.4 million (Q3 2025) per Business Quant data.